Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: follitropin alfa
INDICATION: Anovulation
DATE: 23/06/2014
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
